Robert W Baird Upgrades OPTR To Outperform
Analysts at Robert W Baird upgrade Optimer Pharmaceuticals Inc (NASDAQ: OPTR) from "neutral" to "outperform." The target price for OPTR has been raised from $12 to $14.
OPTR's shares lost 2.47% to close at $9.47 yesterday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Robert W BairdUpgrades Price Target Analyst Ratings
